Reply to B. Ulas Kahya et al and A. Soran et al.
Khan SA, Zhao F, Goldstein L, Sparano J, Sledge G.
J Clin Oncol. 2022 11 20. 40(33):3899-3901. PMID: 35820109
Links
Bibliography
Reply to T. Shimoi et al and Y. Shimanuki et al.
Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD.
J Clin Oncol. 2021 11 01. 39(31):3522-3524. PMID: 34554848
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA.
J Clin Oncol. 2018 06 01. 36(16):1556-1563. PMID: 29664714
Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
Zhao F, Cella D, Manola J, DiPaola RS, Wagner LI, Haas NSB.
Support Care Cancer. 2018 06. 26(6):1889-1895. PMID: 29274030
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS.
Cancer Immunol Res. 2017 06. 5(6):480-492. PMID: 28522460
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).
Garg MK, Zhao F, Sparano JA, Palefsky J, Whittington R, Mitchell EP, Mulcahy MF, Armstrong KI, Nabbout NH, Kalnicki S, El-Rayes BF, Onitilo AA, Moriarty DJ, Fitzgerald TJ, Benson AB.
J Clin Oncol. 2017 Mar. 35(7):718-726. PMID: 28068178
Surrogate End Points and Their Validation in Oncology Clinical Trials.
Zhao F.
J Clin Oncol. 2016 May 01. 34(13):1436-7. PMID: 26951314
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, Kirkwood JM.
J Clin Oncol. 2015 Dec 01. 33(34):4066-76. PMID: 26351350
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE.
J Clin Oncol. 2015 Jul 20. 33(21):2353-60. PMID: 26077235